Understanding the activity of antibody–drug conjugates in primary and secondary brain tumours

Ehrlich, P. The Harben Lectures, 1907. Experimental researches on specific therapeutics. J. R. Inst. Public Health 15, 321–340 (1907).

Google Scholar 

Sievers, E. L. et al. Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. J. Clin. Oncol. 19, 3244–3254 (2001).

Article  CAS  PubMed  Google Scholar 

Younes, A. et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin’s lymphoma. J. Clin. Oncol. 30, 2183–2189 (2012).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Pro, B. et al. Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. J. Clin. Oncol. 30, 2190–2196 (2012).

Article  CAS  PubMed  Google Scholar 

Kantarjian, H. M. et al. Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia. N. Engl. J. Med. 375, 740–753 (2016).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sehn, L. H. et al. Polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma. J. Clin. Oncol. 38, 155–165 (2020).

Article  CAS  PubMed  Google Scholar 

Galsky, M. D. et al. Phase I trial of the prostate-specific membrane antigen-directed immunoconjugate MLN2704 in patients with progressive metastatic castration-resistant prostate cancer. J. Clin. Oncol. 26, 2147–2154 (2008).

Article  CAS  PubMed  Google Scholar 

Milowsky, M. I. et al. Phase 1/2 multiple ascending dose trial of the prostate-specific membrane antigen-targeted antibody drug conjugate MLN2704 in metastatic castration-resistant prostate cancer. Urol. Oncol. Semin. Original Investig. 34, 530.e15–530.e21 (2016).

Article  CAS  Google Scholar 

Verma, S. et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N. Engl. J. Med. 367, 1783–1791 (2012).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rouse, C., Gittleman, H., Ostrom, Q. T., Kruchko, C. & Barnholtz-Sloan, J. S. Years of potential life lost for brain and CNS tumors relative to other cancers in adults in the United States, 2010. Neuro Oncol. 18, 70–77 (2016).

Article  PubMed  Google Scholar 

Siegel, R. L., Miller, K. D., Fuchs, H. E. & Jemal, A. Cancer statistics, 2021. CA Cancer J. Clin. 71, 7–33 (2021).

Article  PubMed  Google Scholar 

Lamba, N., Wen, P. Y. & Aizer, A. A. Epidemiology of brain metastases and leptomeningeal disease. Neuro Oncol. 23, 1447–1456 (2021).

Article  PubMed  PubMed Central  Google Scholar 

Sperduto, P. W. et al. Survival in patients with brain metastases: summary report on the updated diagnosis-specific graded prognostic assessment and definition of the eligibility quotient. J. Clin. Oncol. 38, 3773–3784 (2020).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bartsch, R. et al. Trastuzumab deruxtecan in HER2-positive breast cancer with brain metastases: a single-arm, phase 2 trial. Nat. Med. 28, 1840–1847 (2022).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Pérez-García, J. M. et al. Trastuzumab deruxtecan in patients with central nervous system involvement from HER2-positive breast cancer: the DEBBRAH trial. Neuro Oncol. https://doi.org/10.1093/neuonc/noac144 (2022).

Article  PubMed Central  Google Scholar 

Kabraji, S. et al. Preclinical and clinical efficacy of trastuzumab deruxtecan in breast cancer brain metastases. Clin. Cancer Res. https://doi.org/10.1158/1078-0432.CCR-22-1138 (2022).

Article  PubMed Central  Google Scholar 

Lassman, A. B. et al. Depatuxizumab mafodotin in EGFR-amplified newly diagnosed glioblastoma: a phase III randomized clinical trial. Neuro Oncol. 25, 339–350 (2023).

Article  PubMed  Google Scholar 

Cobleigh, M. A. et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J. Clin. Oncol. 17, 2639–2648 (1999).

Article  CAS  PubMed  Google Scholar 

Slamon, D. J. et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244, 707–712 (1989).

Article  CAS  PubMed  Google Scholar 

Robertson, K. W. et al. Quantitative estimation of epidermal growth factor receptor and c-erbB-2 in human breast cancer. Cancer Res. 56, 3823–3830 (1996).

CAS  PubMed  Google Scholar 

Drago, J. Z., Modi, S. & Chandarlapaty, S. Unlocking the potential of antibody–drug conjugates for cancer therapy. Nat. Rev. Clin. Oncol. 18, 327–344 (2021).

Article  PubMed  PubMed Central  Google Scholar 

Khongorzul, P., Ling, C. J., Khan, F. U., Ihsan, A. U. & Zhang, J. Antibody–drug conjugates: a comprehensive review. Mol. Cancer Res. 18, 3–19 (2020).

Article  CAS  PubMed  Google Scholar 

Jain, N., Smith, S. W., Ghone, S. & Tomczuk, B. Current ADC linker chemistry. Pharm. Res. 32, 3526–3540 (2015).

Article  CAS  PubMed  PubMed Central  Google Scholar 

van der Velden, V. H. J. et al. Targeting of the CD33-calicheamicin immunoconjugate Mylotarg (CMA-676) in acute myeloid leukemia: in vivo and in vitro saturation and internalization by leukemic and normal myeloid cells. Blood 97, 3197–3204 (2001).

Article  PubMed  Google Scholar 

Cardillo, T. M., Govindan, S. V., Sharkey, R. M., Trisal, P. & Goldenberg, D. M. Humanized anti-Trop-2 IgG-SN-38 conjugate for effective treatment of diverse epithelial cancers: preclinical studies in human cancer xenograft models and monkeys. Clin. Cancer Res. 17, 3157–3169 (2011).

Article  CAS  PubMed  Google Scholar 

Ogitani, Y. et al. DS-8201a, a novel HER2-targeting ADC with a novel DNA topoisomerase I inhibitor, demonstrates a promising antitumor efficacy with differentiation from T-DM1. Clin. Cancer Res. 22, 5097–5108 (2016).

Article  CAS  PubMed  Google Scholar 

Zhang, D. et al. Catalytic cleavage of disulfide bonds in small molecules and linkers of antibody–drug conjugates. Drug Metab. Dispos. 47, 1156–1163 (2019).

Article  CAS  PubMed  Google Scholar 

Li, F. et al. Intracellular released payload influences potency and bystander-killing effects of antibody–drug conjugates in preclinical models. Cancer Res. 76, 2710–2719 (2016).

Article  CAS  PubMed  Google Scholar 

Khera, E. et al. Cellular-resolution imaging of bystander payload tissue penetration from antibody–drug conjugates. Mol. Cancer Ther. 21, 310–321 (2022).

Article  CAS  PubMed  Google Scholar 

Hamblett, K. J. et al. Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate. Clin. Cancer Res. 10, 7063–7070 (2004).

Article  CAS  PubMed  Google Scholar 

Lyon, R. P. et al. Reducing hydrophobicity of homogeneous antibody–drug conjugates improves pharmacokinetics and therapeutic index. Nat. Biotechnol. 33, 733–735 (2015).

Article  CAS  PubMed  Google Scholar 

Lu, G. et al. Co-administered antibody improves penetration of antibody–dye conjugate into human cancers with implications for antibody–drug conjugates. Nat. Commun. 11, 5667 (2020).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kaempffe, A. et al. Effect of conjugation site and technique on the stability and pharmacokinetics of antibody–drug conjugates. J. Pharm. Sci. 110, 3776–3785 (2021).

Article  CAS  PubMed  Google Scholar 

Lewis Phillips, G. D. et al. Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody–cytotoxic drug conjugate. Cancer Res. 68, 9280–9290 (2008).

Article  CAS  PubMed  Google Scholar 

Kline, T. et al. Methods to make homogenous antibody drug conjugates. Pharm. Res. 32, 3480–3493 (2015).

Article  CAS  PubMed  Google Scholar 

Diéras, V. et al. Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial. Lancet Oncol. 18, 732–742 (2017).

Article  PubMed  PubMed Central  Google Scholar 

Krop, I. E. et al. Trastuzumab emtansine versus treatment of physician’s choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial. Lancet Oncol. 18, 743–754 (2017).

Article  CAS  PubMed  Google Scholar 

留言 (0)

沒有登入
gif